UTHR•United Therapeutics and Liquidia entered a settlement under which Liquidia will pay United Therapeutics $330.40 million. Liquidia will stop selling Yutrepia for PH-ILD upon FDA approval and limit marketing to practitioners treating PAH.
Liquidia will pay United Therapeutics $330.40 million under the settlement. The parties will seek dismissal of the litigation within 10 days after a $185 million payment.
Upon FDA approval, Liquidia will cease sales of Yutrepia with the PH-ILD indication and market the drug only to practitioners treating PAH. Liquidia will also terminate the ASCENT trial cohorts studying PH-ILD and cease publication of data.
